Neuropathy and Anti-GFAP Antibodies

Active, not recruiting

• Conditions: Neurological Diseases Associated to Anti GFAP Antibodies; Neurological Diseases or Conditions
• Interventions: Other: Clinical examination; Other: electroneuromyography (ENMG)

• Registration Number: NCT05742087
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Anti-Glial Fibrillary Acidic Protein (GFAP) are antibodies associated to inflammatory diseases of the central nervous system. The GFAP protein is highly expressed by astrocytes explaining these syndromes, but GFAP is also expressed by immature and non-myelinating Schwann cells. Thus, these antibodies could also lead to damages of the peripheral nervous system (PNS). Moreover, such damages have already been reported on small studies, and there is a need for larger cohorts.

The investigators will use the cohort of patients with neurological syndromes and anti-GFAP antibodies identified in the cerebrospinal fluid (CSF) of the "Reference center for paraneoplastic neurological syndromes and autoimmune encephalitis" to determine the frequency of the PNS involvement in these patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-09-01
• Primary Completion: 2022-10-01
• Study First Submitted: 2022-12-01
• Status Verified: 2023-02
• Study First Submitted QC: 2023-02-14
• Last Update Submitted: 2023-02-14
• Study First Posted: 2023-02-23
• Last Update Posted: 2023-02-23
• Study Completion: 2023-05-01

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• • Age > 18 years old
• Neurological symptoms
• Anti-GFAP antibodies identified in the CSF

Exclusion Criteria

• • Uncomplete data in the medical records of patients

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients presenting with neurological symptoms and anti-GFAP antibodies in the CSF.	Clinical examination	This is a non-interventional study involving biological samples. Samples are already stored in biobank repositories and collected as part of "good clinical practice" in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the "iological Resource Center of the Hospices Civils de Lyon" (CRB-HCL) (including tissue, cells or biological fluids). The group will be composed of patients included in the French cohort of patients with neurological syndromes and anti-GFAP antibodies in the CSF.
Patients presenting with neurological symptoms and anti-GFAP antibodies in the CSF.	electroneuromyography (ENMG)	This is a non-interventional study involving biological samples. Samples are already stored in biobank repositories and collected as part of "good clinical practice" in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the "iological Resource Center of the Hospices Civils de Lyon" (CRB-HCL) (including tissue, cells or biological fluids). The group will be composed of patients included in the French cohort of patients with neurological syndromes and anti-GFAP antibodies in the CSF.

Primary Outcome Measures

Name	Time	Method
Cranial nerves abnormality at clinical examination of abnormal ENMG	Immediately after diagnosis	Data concerning the clinical examination and the ENMG will be extracted from the cohort of patients with neurological syndroms and anti-GFAP antibodies identified in the cerebrospinal fluid (CSF) of the "Centre de reference des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes".

Trial Locations

Locations (1)

Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites autoimmunes; 🇫🇷 Lyon, France